• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Harrow

    Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S.
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow Announces New $100 Million Secured Credit Facility with Oaktree
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow Launches Next-Generation Compounded Atropine Formulations
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow Prices $25 Million Offering
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow and iOR Partners Expand National Product Supply Agreement
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow Announces Third Quarter 2022 Financial Results
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow Launches Atropine.com
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow Sells Non-Ophthalmic Compounding Business
    From Harrow
    Via Business Wire
    Tickers HROW
    ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation
    From Harrow
    Via Business Wire
    Tickers HROW
    Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia
    From Harrow
    Via Business Wire
    Tickers HROW
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.